Photo 51 Rosalind Franklin's logo

Department of Physiology and Biophysics


Email: physiology@rosalindfranklin.edu
Fax: 847.578.3265

Department of Physiology and Biophysics


Email: physiology@rosalindfranklin.edu
Fax: 847.578.3265
 
Web Site Search
 
 
Darryl R. Peterson, Ph.D.
Professor of Physiology & Biophysics

Phone: 847-578-3274
Fax: 847-578-3265
E-mail: darryl.peterson@rosalindfranklin.edu		 /DNN/Portals/24/Images/Physiology/Peterson.jpg

 

Blood-Brain Barrier Physiology, Pathophysiology of Stroke,
Renal Pathophysiology, Treatment for Diabetic Nephropathy

Current studies in our laboratory focus on: 1) functional properties of the blood-brain barrier, and prevention of injury to the blood-brain barrier associated with ischemic stroke; and 2) renal pathophysiology, and treatment and prevention of renal fibrosis associated with diabetic nephropathy.
 
The blood-brain barrier includes cerebral capillary endothelial cells that are sensitive to reperfusion injury associated with delayed thrombolysis following ischemic stroke. This can result in cerebral bleeding termed “hemorrhagic transformation”, culminating in death. We have been studying the cellular mechanisms responsible for blood-brain barrier injury and hemorrhagic transformation. Potential therapeutics for treatment of stroke, and protection of the cerebral vasculature under conditions of stroke, have been identified and tested.
 
Renal fibrosis associated with diabetes mellitus can contribute to chronic renal failure. We have been studying the cellular and molecular events responsible for renal fibrosis and diabetic nephropathy, including the design and development of drugs for treatment of these conditions. 

 

Recent Publications (selected):

Peterson, D.R. and R.A. Hawkins. Transport studies using membrane vesicles. In: Blood-Brain Barrier: Biology and Protocols. Humana Press, Inc. Totowa. Pp, 233-247, 2003.
 
Neuwelt, E.A., M.A. Pagel, D.F. Kraemer, D.R. Peterson, and L.L. Muldoon. Bone marrow chemoprotection without compromise of chemotherapy efficacy in rat brain tumor model. J. Pharmacol. Exp. Ther. 309: 1-6, 2004.
 
Doolittle, N.D., L.E. Abrey, W.A. Bleyer, S. Brem, T. Davis, P. Dorey-Duffy, L.R. Drewes, W.A. Hall, J.M. Hoffman, A.Korfel, R. Martuza, L.L. Muldoon, D. Peereboom, D.R. Peterson, S.D. Rabkin, Q. Smith, G. Stevens, and E.A. Neuwelt. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting. Cancer Res. 11: 421-428, 2005.
 
Peterson, D.R.  Blood-brain barrier. In: Encyclopedia of Life Sciences. Macmillan Reference Ltd., London, 2005.
 
Riser, B.L., S. Karoor, and D.R. Peterson. CCN genes and the kidney. In: CCN proteins: a new family of cell growth and differentiation regulators. B. Perbal and M. Takigawa, eds. Imperial College Press, UK, pp. 95-116, 2005.
 
Doolittle, N.D., D.M. Peereboom, G.A. Christoforidis, W.A. Hall, W.A., D. Palmieri, P.R. Brock, K. Campbell, D.T. Dickey, L.L. Muldoon, B.P. O’Neill, D.R. Peterson, B. Pollock, C. Soussain, Q. Smith, R.M. Tyson, and E.A. Neuwelt. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection in primary and metastatic brain tumors: report of the eleventh annual blood-brain barrier consortium meeting. J. Neuro-Oncology, 2006.
 
Cooker, L., D.R. Peterson, J. Rambow, M. Riser, R. Riser, F. Najmabadi, D. Brigstock, and B. Riser. TNF-alpha, but not IFN-gamma, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am. J. Physiol. F157-F165, 2007.
 
Dickey, D.T., L. L. Muldoon, N.D. Doolittle, D. R. Peterson, D.F. Kraemer, and E. A. Neuwelt.  Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced nephrotoxicity in rat models. Cancer Chemother. Pharmacol. 62: 235-241, 2008.
 
Stenstrom, D.A., L.L. Muldoon, H. Armijo-Medina, S. Watnick, N. D. Doolittle, J. A. Kaufman, D.R. Peterson, J. Bubalo, and E.A. Neuwelt. Can N-acetylcysteine prevent contrast induced nephropathy: Premature phase III trials. J. Vasc. Interven. Radiol. 19: 309-318, 2008.
 
Riser, B.L., F. Najmabadi, B. Perbal, D.R. Peterson, J. Rambow, M.L. Riser. E. Sulowski, H. Yeger, and S.C. Riser. CCN3 (Nov) is a negative regulator of CCN2 (CTGF) and an endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am. J. Pathol. 174: 1725-1734 2009.
 
Riser, B.L., F. Najmabadi, B. Perbal, , J. Rambow, M.L. Riser. E. Sukowski, H. Yeger, S.C. Riser, and D.R. Peterson.  CCN3 (Nov): A negative regulator of CCN2 (CTGF) activity and an endogenous inhibitor of fibrosis in experimental diabetic nephropathy. In: CCN Proteins in Health and Disease. B. Perbal (ed.), pp. 163-181. Springer Science and Business Media, 2010.
 
Riser, B.L., F. Najmabadi, B. Perbal, J. Rambow, M.L. Riser, E. Sukowski, H. Yeger, S.C. Riser, and D.R. Peterson. CCN2/CCN3 regulation and the fibrosis of diabetic renal disease. J. Cell Comm. Signaling 4: 39-50, 2010.
 
Hawkins R.A., J.R. Viña, D.R. Peterson, R. O’Kane, A. Mokashi, and I. A. Simpson. Amino acid transport across each side of the blood-brain barrier. In: Amino Acids in Nutrition and Health. J.P.F. D’Mello, ed. CABI, Oxford,  In Press.   
 
   Site Login   Email   D2L   Site index   Events Calendar   Media/Press   Map & Directions   Directory   inSite   Phone Directory
                        Rosalind Franklin University of Medicine and Science - 3333 Green Bay Rd, North Chicago, IL 60064    (847) 578-3000